Neurovascular Research Laboratory, Vall d'Hebron Research Institute, Universitat Autònoma de Barcelona, Passeig Vall d'Hebron, 119-129, Mediterranean Building, 1st floor, lab 106, Barcelona, 08035, Spain.
Department of Bioquímica i Biologia Molecular i Institut de Neurociències, Universitat Autònoma de Barcelona, Bellaterra (Barcelona), Spain.
Alzheimers Res Ther. 2024 Jul 29;16(1):169. doi: 10.1186/s13195-024-01541-5.
Cerebral amyloid angiopathy (CAA) is characterized by amyloid-β (Aβ) deposition in cerebral vessels, leading to lobar cerebral microbleeds (CMB) and intracerebral hemorrhages (ICH). Apolipoprotein J (ApoJ) is a multifunctional chaperone related to Aβ aggregation and clearance. Our study investigated the vascular impact of chronic recombinant human Apolipoprotein J (rhApoJ) treatment in a transgenic mouse model of β-amyloidosis with prominent CAA.
Twenty-month-old APP23 C57BL/6 mice received 25 doses of rhApoJ (1 mg/kg) (n = 9) or saline (n = 8) intraperitoneally for 13 weeks, while Wild-type (WT) mice received saline (n = 13). Postmortem brains underwent T2*-weighted magnetic resonance imaging (MRI) to detect hemorrhagic lesions. Aβ levels and distribution, cerebral fibrinogen leakage, brain smooth muscle actin (sma), and plasma matrix metalloproteinases and inflammatory markers were analyzed after treatments. Additionally, plasma samples from 22 patients with lobar ICH were examined to determine the clinical relevance of the preclinical findings.
rhApoJ-treated APP23 presented fewer cortical CMBs (50-300 μm diameter) (p = 0.012) and cortical larger hemorrhages (> 300 μm) (p = 0.002) than saline-treated mice, independently of Aβ brain levels. MRI-detected hemorrhagic lesions correlated with fibrinogen cerebral extravasation (p = 0.011). Additionally, rhApoJ-treated mice presented higher number of sma-positive vessels than saline-treated mice (p = 0.038). In rhApoJ-treated mice, human ApoJ was detected in plasma and in occasional leptomeningeal vessels, but not in the parenchyma, suggesting that its mechanism of action operates through the periphery. The administration of rhApoJ induced an increase in plasma Groα (p = 0.035) and MIP-1α (p = 0.035) levels, while lower MMP-12 (p = 0.046) levels, compared to the saline-treated group. In acute lobar ICH patients, MMP-12 plasma levels correlated with larger hemorrhage volume (p = 0.040) and irregular ICH shape (p = 0.036).
Chronic rhApoJ treatment in aged APP23 mice ameliorated CAA-related neurovascular damage by reducing the occurrence of CMB. We propose that rhApoJ may prevent blood-brain barrier (BBB) leakage and CMB appearance partly through circulating MMP-12 modulation.
脑淀粉样血管病(Cerebral amyloid angiopathy,CAA)的特征是β淀粉样蛋白(Aβ)在脑内血管中沉积,导致脑叶微出血(lobar cerebral microbleeds,CMB)和脑出血(intracerebral hemorrhages,ICH)。载脂蛋白 J(Apolipoprotein J,ApoJ)是一种与 Aβ聚集和清除有关的多功能伴侣蛋白。我们的研究旨在探讨慢性重组人载脂蛋白 J(recombinant human Apolipoprotein J,rhApoJ)治疗β淀粉样蛋白沉积为主的转基因小鼠模型中对血管的影响。
20 月龄的 APP23 C57BL/6 小鼠接受 25 次 rhApoJ(1mg/kg)(n=9)或生理盐水(n=8)腹腔内注射,共 13 周,而野生型(Wild-type,WT)小鼠接受生理盐水(n=13)。死后的大脑进行 T2*-加权磁共振成像(Magnetic resonance imaging,MRI)以检测出血性病变。在治疗后分析 Aβ 水平和分布、脑纤维蛋白原漏出、脑平滑肌肌动蛋白(smooth muscle actin,sma)、血浆基质金属蛋白酶和炎症标志物。此外,检测了 22 例脑叶 ICH 患者的血浆样本,以确定临床前发现的临床相关性。
与生理盐水治疗组相比,rhApoJ 治疗的 APP23 小鼠皮层 CMB(50-300μm 直径)(p=0.012)和皮层较大出血(>300μm)(p=0.002)明显减少,与脑内 Aβ 水平无关。MRI 检测到的出血性病变与纤维蛋白原脑外渗有关(p=0.011)。此外,rhApoJ 治疗的小鼠中 SMA 阳性血管的数量也高于生理盐水治疗的小鼠(p=0.038)。在 rhApoJ 治疗的小鼠中,在血浆和偶发性软脑膜血管中检测到人 ApoJ,但在脑实质中未检测到,表明其作用机制通过外周发挥作用。rhApoJ 治疗组的血浆 Groα(p=0.035)和 MIP-1α(p=0.035)水平升高,而 MMP-12(p=0.046)水平降低,与生理盐水治疗组相比。在急性脑叶 ICH 患者中,MMP-12 血浆水平与较大的出血体积(p=0.040)和不规则 ICH 形状(p=0.036)相关。
在老年 APP23 小鼠中,慢性 rhApoJ 治疗可通过减少 CMB 的发生来改善与 CAA 相关的神经血管损伤。我们提出,rhApoJ 可能通过调节循环 MMP-12 来预防血脑屏障(Blood-brain barrier,BBB)渗漏和 CMB 出现。